Empagliflozin reduced risk of death and hospitalisation for heart failure by 25 per cent in adults
Results from the Phase III EMPEROR-Reduced trial were published in The New England Journal of Medicine
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.